Trial
NCT02009384
Ipilimumab Administered to Stage IIIC Stage IV Melanoma After Reg. T Cell Depletion With Denileukin Diftitox
Phase IITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
University of Louisville
Collaborators
James Graham Brown Cancer Center
Condition
Metastatic Melanoma
Intervention
Ipilimumab
Why stopped
low enrollment r/t requirement of prior treatment with denileukin diftitox
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2021-10-25